CAR-T Therapy

A single infusion of Johnson & Johnson's Carvykti rendered all 20 patients in a Dana-Farber phase 2 trial undetectable for residual disease, the first time CAR-T therapy has been tested in a precursor cancer setting.

A two-particle gene-editing system published in Nature creates functional CAR-T cells in vivo, eliminating the costly weeks-long manufacturing process and clearing leukemia, myeloma, and solid tumors in preclinical models.